Samsung Biologics Launches CHF 4.6 Billion Tender Offer for Swiss Peptide CDMO PolyPeptide — BigGo Finance
South Korea’s Samsung Biologics (207940.KS) formally published its tender offer prospectus on August 31, under which it will…
Samsung Biologics Plans Record 3 Trillion Won Share Sale for Swiss Deal
▲ AI PRISM* Personalized Economic Briefing * Editor’s note: AI PRISM (Personalized Report & Insight Summarizing Media) is…
Samsung Biologics Acquires Swiss Peptide CDMO PolyPeptide Group for approximately $1.8 Billion — BigGo Finance
Samsung Biologics (207940) has placed a major bet on capturing the global peptide contract development and manufacturing organization…
Samsung Biologics to Acquire Swiss Peptide CDMO for approximately $1.8 Billion, Targeting Obesity Drug Market — BigGo Finance
Samsung Biologics (207940.KS) announced on the 20th that it will acquire PolyPeptide Group, a global peptide contract development…